December 8, 2011. Dr. Diana Zuckerman spoke at the FDA meeting on the safety of Bayer’s birth control pills Yasmin and Yaz and other drospirenone birth control products, advocating for these high risk drugs to be taken off the market.
Read More »We’re Speaking Out on Health Issues
NCHR scientists and health policy experts provide written and oral statements on a wide range of topics.
Here are many of the ways we have been Speaking Out on Health Policy Issues for the last few years. Whether the topic is legislation intended to cure diseases, proposed bans on BPA or other chemicals that disrupt your hormones, the importance of including women, people of color, and patients over 65 in clinical trials, or many other topics, you’ll gain a better understanding of our evidence-based analyses by reading these letters, statements, and testimony.
Here are the ways we have been Speaking out on Medical Treatments and Products, such as prescription drugs and medical devices that the FDA is considering approving, or is considering taking off the market because of serious risks. Whether the topic is Chantix, Addyi, Yaz, Essure, or medical products you’ve never heard of, you can find out more about what is known and not known about the safety and effectiveness of a wide range of products by looking through this section of our website.
NCHR Testimony at the Senate Aging Committee Hearing on Atypical Antipsychotic Drugs
November 30, 2011. Dr. Diana Zuckerman, the president of NRC, provided a statement for the Senate Aging Committees regarding problems with antipsychotic drugs.
Read More »Keeping Safeguards That Protect Our Health
November 29, 2011. NCHR signs on to a letter opposing the Regulatory Accountability Act (RAA) (H.R. 3010/S. 1606) and the Regulations from the Executive in Need of Scrutiny (REINS) Act of 2011 (H.R. 10/S. 299) to protect a safe food supply, clean air and water, and a variety of consumer protections for American families.
Read More »NCHR Testimony at the Public Meeting on Prescription Drug User Fee Act (PDUFA) Reauthorization
October 5, 2011. “Everyone in this room agrees that we want safe and effective drugs to be on the market in the U.S. as soon as possible. Where we don’t always agree, however, is what is appropriate evidence of what is safe or effective, and how to weigh the potential risks and potential benefits.”
Read More »NCHR Testimony at the FDA Advisory Committee Meeting on Breast Implants
October 24, 2011. Dana Casciotti, NCHR Public Health Research Director, testifies at an FDA advisory meeting on breast implants.
Read More »